About CalciMedica
CalciMedica is a company based in San Diego (United States) founded in 2006 by Kenneth Stauderman. CalciMedica has raised $76.66 million across 16 funding rounds from investors including Biogen, HHS and Avenue Capital Group. The company has 14 employees. CalciMedica offers products and services including Auxora and CRAC Channel Inhibitors. CalciMedica operates in a competitive market with competitors including Nimbus Therapeutics, Escient Pharmaceuticals, Aclaris Therapeutics, Alpine Immune Sciences and Septerna, among others.
- Headquarter San Diego, United States
- Employees 14
- Founders Kenneth Stauderman
- Stage Public
- SectorsHealthcare
- Website calcimedica.com
- Social LinkedIn X
- Legal Name Calcimedica, Inc.
- Net Profit-$29.56 M (USD)-115.78as on Dec 31, 2025
- EBITDA-$23.07 M (USD)4.44as on Dec 31, 2025
- Total Equity Funding$76.66M (USD)
in 16 rounds
- Latest Funding Round$32.5M (USD), Debt – Conventional
Apr 2025
- InvestorsBiogen
& 7 more
- Employee Count14
Products & Services of CalciMedica
CalciMedica offers a comprehensive portfolio of products and services, including Auxora and CRAC Channel Inhibitors.
CRAC channel inhibitor targeting inflammatory diseases in pancreas and kidney
Modulates immune responses for lung and organ inflammation treatments
Funding Insights of CalciMedica
CalciMedica has successfully raised a total of $76.66M across 16 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $32.5 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $76.66M
- Total Rounds 16
- Last Round Debt – Conventional — $32.5M
- First Round $1.5M
(Jul 2007)
- Investors Count 8
Latest 10 of 16 funding rounds of CalciMedica with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2025 | $32.5M | Debt – Conventional | – | – | |
| Apr 2023 | $10.34M | Post-IPO | – | – | – |
| May 2020 | $17.19M | Series C | – | Valence Life Sciences | |
| Sep 2014 | $145,496 | Grant | – | – | |
| May 2014 | $150,176 | Grant | – | – | |
| Apr 2014 | $2.5M | Series C | – | – | – |
| Mar 2014 | $187,358 | Grant | – | – | |
| Jul 2013 | $3M | Series C | – | – | – |
| Oct 2012 | $4.6M | Series C | – | – | – |
| Mar 2012 | $13.2M | Series C | – | – | – |
8 investors in total: 8 institutional.
Investors in CalciMedica
CalciMedica has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Biogen, HHS and Avenue Capital Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diversified investments in distressed debt and securities are managed globally. | 1995 | avenuecapital.com | New York, United States | |
- | – | valencefund.com | - | |
- | – | mesaverdevp.com | - | |
Biomedical investment financing and active management services. | – | sanderling.com | - | |
Bering Capital is engaged in healthcare investment and company building. | – | beringcapital.com | San Francisco, United States | |
A biotechnology venture capital firm investing in innovative science. | – | srone.com | - | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Therapies for neurodegenerative and immunology disorders are developed. | 1978 | biogen.com | Cambridge, United States |
Investor details for CalciMedica
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CalciMedica
20 people are tracked at CalciMedica (11 in leadership, 6 in board & advisors, 3 in team); the tracked headcount is 14.
| Name | Role | Group |
|---|---|---|
Kenneth Stauderman | Co-Founder & CSO | Leadership |
Michael J. Dunn | President & COO | Leadership |
A. Rachel Leheny | CEO | Leadership |
Katherine Randolph | Sr. Director, Clinical Operations | Leadership |
Sudarshan Hebbar | CMO | Leadership |
Sean P. Lawler | VP, Finance | Leadership |
Eric W. Roberts | Chief Business Officer | Leadership |
Daniel Geffken | Interim CFO | Leadership |
Liisa Tingue | Vice President Clinical Operations | Leadership |
Stephen Bardin | Chief Financial Officer | Leadership |
Raven D. Jaeger | Chief Regulatory Officer | Leadership |
Zafi Avnur | Director | Board & advisors |
Robert N. Wilson | Chairman | Board & advisors |
Fred Middleton | Director | Board & advisors |
Allan L. Shaw | Director | Board & advisors |
Fred Guerard | Director | Board & advisors |
Eric Bjerkholt | Director | Board & advisors |
Kenneth A. Stauderman | CSO | Team |
Andrew Cunningham | SVP, Clinical Development | Team |
John M. Dunn | Acting General Counsel | Team |
Complete people profiles for CalciMedica
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of CalciMedica
CalciMedica is a publicly listed company on the NASDAQ with ticker symbol CALC in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date25 Sep 2020
- Listed onNASDAQ: CALC
- Listed entityCalciMedica, Inc.
- Exchange sectorHealth technology
- ISINUS38942Q3011
- Share price$1.27 (-2.31% on the day) · 2026-10-09
- Market capitalisation$8.7M
- EPS (diluted, trailing year)$-6.79
- Volume (last session)82,148
Financials of CalciMedica
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | – | -$29.6M | -$23.1M |
| 2024 | – | -$13.7M | -$24.1M |
| 2023 | – | -$34.4M | -$21.8M |
| 2022 | – | -$9.1M | -$14.1M |
| 2021 | – | -$35.8M | -$35.4M |
Detailed financial statements for CalciMedica
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of CalciMedica
4 dated milestones of CalciMedica across 19 years, from founding to its latest funding, stage changes and deals.
- Founded CalciMedica is founded.
- Funding First funding round of $1.5M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Debt – Conventional, of $32.5M.
Competitors of CalciMedica
CalciMedica operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nimbus Therapeutics, Escient Pharmaceuticals, Aclaris Therapeutics, Alpine Immune Sciences and Septerna, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| escientpharma.com | 2017 | San Diego, United States | $237.5M | 44 | Small molecule therapeutics for inflammatory diseases are developed. | |
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. | |
| alpineimmunesciences.com | 2015 | Seattle, United States | $49.25M | 126 | Developer of immunotherapies to treat cancer and autoimmune disorders | |
| septerna.com | 2020 | San Bruno, United States | $250M | – | GPCR drug discovery platform is developed for multiple diseases. | |
| upstreambio.com | 2021 | Waltham, United States | $400M | – | Therapeutics for allergic and inflammatory diseases are developed. | |
| gossamerbio.com | 2017 | San Diego, United States | $330M | 102 | Developer of small molecule-based therapies for treating immunological disorders, inflammation, and cancer | |
| acelyrin.com | 2020 | Los Angeles, United States | $550M | – | Immunological drug candidates are developed for severe diseases. |
Detailed competitors of CalciMedica
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of CalciMedica
The website of CalciMedica (calcimedica.com) receives about 9.1K visits a month.
- Monthly visits9.1K
▲ 74.7% vs previous month
Latest news on Calcimedica
Complete news archive for CalciMedica
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to CalciMedica
10 companies that operate in the same segment as CalciMedica (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about CalciMedica
CalciMedica was founded in 2006 and raised its 1st funding round 1 year after it was founded.
CalciMedica is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
CalciMedica is a funded company, having raised a total of $76.66M across 16 funding rounds to date. The company's 1st funding round was a Series C of $13.2M, raised on Jul 2007.
CalciMedica has 14 employees.
CalciMedica was established in 2006 in San Diego, United States, within the biotechnology sector. A portfolio of selective CRAC channel inhibitor drugs is being advanced by the company to address acute inflammatory conditions. Development efforts are directed toward enhancing patient outcomes in these indications, with operations centered on pharmaceutical innovation for inflammatory diseases.
CalciMedica's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
CalciMedica offers Auxora and CRAC Channel Inhibitors.
Yes, CalciMedica is publicly traded on NASDAQ under the ticker symbol CALC.
CalciMedica has 8 investors. Key investors include Biogen, HHS, Avenue Capital Group, Valence Life Sciences, and Mesa Verde Venture Partners.
CalciMedica operates through Calcimedica, Inc..